HANDOUT. for. C008 Live Demonstration: The State of the Art of Aesthetic Dermatology. Director: Seth L. Matarasso, MD

Transcription

1 HANDOUT for C008 Live Demonstration: The State of the Art of Aesthetic Dermatology Director: Seth L. Matarasso, MD

2 COURSE INFORMATION Director: Seth L. Matarasso, MD Invited Speakers: Tina S. Alster, MD Kimberly J. Butterwick, MD Joel Cohen, MD Sue Ellen Cox, MD Lisa Donofrio, MD Sabrina Fabi, MD Mitchel Paul Goldman, MD George Hruza, MD, MBA Lorrie Klein, MD Naomi Lawrence, MD Stephen H. Mandy, MD Gary Monheit, MD Melanie Palm, MD, MBA E. Victor Ross, MD Adam Rotunda, MD Susan H. Weinkle, MD LEARNING OBJECTIVES Following this course, the attendee should be able to: 1. Assess the aging face and neck and choose the most appropriate injection techniques. 2. Identify soft tissue fillers and their appropriate uses. 3. Recognize and identify facial and neck anatomy as it relates to the use of cosmetic injections. DESCRIPTION This live interactive session will feature experts from around the country demonstrating their techniques and treatment tips with cosmetic injections. Attendees will observe in a live interactive manner precisely how the faculty assess aging faces and go about treating the various areas of the face from brow to neck. Each area will be treated by one of the faculty while another guides the procedure and facilitates dialogue with the audience. There will be discussion and demonstration of the optimal techniques using many of the FDA approved fillers, neuromodulators, and deoxycholic acid Category 1 CME Credits SCHEDULE Friday, February 16, :00 p.m. Introduction / Dr. Matarasso 1:10 p.m. Upper Face Rejuvenation: Treatment of the Glabellar Complex, Forehead, Periocular Area and Temples / Dr. Klein and Dr. Lawrence 1:30 p.m. Midface Volume Replacement And Volumizing The Cheeks / Dr. Palm and Dr. Cohen 1:50 p.m. Peri-Oral Rejuvenation And Lip Augmentation / Dr. Donofrio and Dr. Mandy 2:10 p.m. Treatment of the Jaw Line, Neck And Masseter / Dr. Fabi and Dr. Cox 2:30 p.m. Submental Fat Reduction Without Surgery / Dr. Goldman and Dr. Rotunda 2:45 p.m. Non-Facial Aesthetic Treatments (Hands) / Dr. Butterwick and Dr. Monheit 3:05 p.m. Microneedling and PRP / Dr. Ross and Dr. Alster 3:25 p.m. Suture Lifts: The New Face of Rhytidectomy / Dr. Weinkle and Dr. Hruza 3:50 p.m. Panel Questions and Answers 2

3 FACULTY DISCLOSURES Alster, Tina S., MD: Home Skinovations C(ST); Merz Aesthetics C(OB); Revance Therapeutics, Inc. I(Grants/Research Funding); Sente Labs I(EQ); Butterwick, Kimberly J., MD: Allergan, Inc I(Grants/Research Funding); Allergan, Inc. A(H); Colorescience A(H); Galderma Laboratories, L.P. A(H); Merz Pharmaceuticals, LLC A(H); ThermiAesthetics C(H); Valeant Pharmaceuticals International C(H); Cohen, Joel Lee, MD: Allergan, Inc. C(H), I(Grants/Research Funding); Galderma USA C(H), I(Grants/Research Funding); LEO Pharma, US I(Grants/Research Funding); Merz Pharmaceuticals, LLC C(H); Revance Therapeutics, Inc. I(Grants/Research Funding); Sciton Inc. C(H); Cox, Sue Ellen, MD: Allergan, Inc. A(H), I(OB); Bayer Pharmaceuticals I(OB); Candesant Biomedical, Inc. SH(ST); Cearna, Inc A(SO); Croma-Pharma GmbH Austria I(OB); Evolus, Inc. I(OB); Galderma Laboratories, L.P. Speaker/Faculty Education(H); Merz Aesthetics SP(H); Neothetics I(OB); Revance Therapeutics, Inc. I(OB); TEOXANE Laboratories I(OB); TruInject Medical Corporation SH(ST); Valeant Pharmaceuticals North America LLC C(H); Donofrio, Lisa M., MD: Allergan, Inc. A(H), I(OB); American Society of Dermatologic Surgery B(None Chosen); Canfield Scientific, Inc. O(H); Fotofinder I(H); Galderma Laboratories, L.P. I(None Chosen); Galderma USA C(H); Journal of Dermatologic Surgery O(NC), O(None Chosen); Kythera I(Grants/Research Funding); Mentor Corporation I(H), I(OB); Merz Pharmaceuticals, LLC I(OB); Revance Therapeutics, Inc. I(OB); Sienna Biopharmaceuticals I(Grants/Research Funding); Fabi, Sabrina G., MD: Alastin Skincare, Inc A(H); Allergan, Inc Speaker/Faculty Education(H); Bayer I(Grants/Research Funding); Colorescience I(Grants/Research Funding), Speaker/Faculty Education(H); Galderma Laboratories, LP SP(H); Merz Aesthetics I(Grants/Research Funding), Speaker/Faculty Education(H); Revance Therapeutics, Inc. A(H), I(Grants/Research Funding); Goldman, Mitchel Paul, MD: Allergan, Inc. A(Grants/Research Funding), I(Grants/Research Funding); DUSA Pharmaceuticals, Inc I(Grants/Research Funding); Galderma USA C(H), I(Grants/Research Funding); Lumenis C(Fees), I(EQ); Merz Aesthetics C(Grants/Research Funding), I(Grants/Research Funding); Sienna Biopharmaceuticals C(Fees), I(Grants/Research Funding); SkinMedica, Inc. C(H); SkinMedica, Inc. I(Grants/Research Funding); Solta Medical I(Grants/Research Funding); Syneron, Inc. I(EQ); Valeant Pharmaceuticals International C(H); Hruza, George J., MD, MBA: Allergan, Inc A(H); Amgen SH(NC); Ascend Pharmaceuticals, Inc. A(H); Express 3

4 Scripts (formerly Medco Health Solutions) SH(NC); Johnson & Johnson Consumer Products Company SH(NC); MD Complete SH(NC); Merck & Co., Inc. SH(NC); Pfizer Inc. SH(NC); Procter & Gamble Company SH(NC); Pulse Biosciences A(H), I(Grants/Research Funding); Teva SH(NC); Unilever SH(NC); Klein, Lorrie J., MD: Alastin Skincare, Inc A(SO), SH(NC); Allergan, Inc SH(NC); Allergan, Inc. Speaker/Faculty Education(H); Alphaeon SH(ST); Cearna, Inc A(SO); Sente Labs A(H), A(SO), SH(NC); Lawrence, Naomi, MD: no financial relationships exist with commercial interests. Mandy, Stephen Howard, MD: Almirall C(S); Procter & Gamble Company C(S); Sinclair Pharma A(H); Matarasso, Seth L., MD: no financial relationships exist with commercial interests. Monheit, Gary D., MD: Allergan, Inc. C(H), I(Grants/Research Funding); Alphaeon I(Grants/Research Funding); Croma-Pharma GmbH Austria I(Grants/Research Funding); Evolus, Inc. I(Grants/Research Funding); Galderma Laboratories, L.P. C(H), I(Grants/Research Funding); Genentech, Inc. SP(H); Merz Pharmaceuticals, LLC C(H); Revance Therapeutics, Inc. C(H), I(Grants/Research Funding); Sienna Biopharmaceuticals I(Grants/Research Funding); Suneva Medical, Inc. C(NC), I(Grants/Research Funding); TEOXANE Laboratories I(Grants/Research Funding); Palm, Melanie, MD: Allergan, Inc A(H); AmperSand Biopharmaceutical, LLC I(Fees); BTL Industries Speaker/Faculty Education(H); Galderma Laboratories, L.P. C(H); Kythera Speaker/Faculty Education(H); Lumenis SP(H); Lutronics, Inc. C(OB); Merz Aesthetics Speaker/Faculty Education(H); Valeant Pharmaceuticals International C(H); Ross, E. Victor, Jr., MD: Candela Corporation A(Grants/Research Funding), I(H); Cutera, Inc. I(EQ), I(Grants/Research Funding); Lumenis I(EQ), I(H); Sebcaia, Inc A(H); Syneron, Inc. I(Grants/Research Funding); Rotunda, Adam M., MD: Kythera A(ST); Weinkle, Susan H., MD: Allergan, Inc C(H), I(H); Allergan, Inc. A(H), SP(H); Alphaeon I(H); Derm Advance I(NC), SH(NC); Ethicon, Inc. A(H), C(H), SP(H); Galderma Laboratories, L.P. C(H), SP(H); Merz Aesthetics A(H), C(H), SP(H); Procter & Gamble Company C(H); Sinclair Pharma C(H), I(H); TEOXANE Laboratories I(H); DISCLOSURE ABBREVIATIONS KEY TYPE OF RELATIONSHIP: A Advisory Board B Board of Directors C Consultant E Employee F Founder I Investigator O Other SP Speaker SH Stockholder NATURE OF COMPENSATION: EQ Equipment (dept. or practice) G Grants H Honoraria IP Intellectual Property Rights NC No Compensation Received OB Other Financial Benefit R Royalty RF Residency or Fellowship Program Funding S Salary ST Stock SO Stock Options RESOLUTION OF CONFLICTS OF INTEREST 4

5 In accordance with the ACCME Standards for Commercial Support of CME, the American Academy of Dermatology has implemented mechanisms, prior to the planning and implementation of this CME activity, to identify and mitigate conflicts of interest for all individuals in a position to control the content of this CME activity. UNAPPROVED USE DISCLOSURE The American Academy of Dermatology requires CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label (not approved for the indications being discussed), unlabeled (not approved for any indications), experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these products/procedures. If you have questions, contact the medical affairs department of the manufacturer for the most recent approval information. Faculty at this meeting will be discussing information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. Following are injectables and devices that will be used at this session: Neurotoxins: BOTOX (onabotulinumtoxina) Dysport (abobotulinumtoxina) Xeomin (incobotulinumtoxina) Hyaluronidase: Vitrase Hylenex Poly-L-lactic Acid: Sculptra Aesthetic Deoxycholic Acid: Kybella Hyaluronic Acids: Belotero Balance Juvéderm Ultra XC Juvéderm Ultra Plus XC Juvéderm Voluma XC Juvéderm Volbella XC Juvéderm Vollure XC Radiesse Radiesse Plus Restylane-Lift Restylane-Silk Restylane-Refyne Restylane-Defyne Devices Microneedling and PRP devices Sutures Silhouette Instalift COMMERCIAL SUPPORT DISCLOSURE At the time of publication of this document, the following commercial interests provided in-kind support for Live Demonstration Sessions: Allergan...Injectables Galderma...Injectables and Topical Anesthetic Merz...Injectables Midmark...Exam Chairs Eclipse...Microneedling and PRP devices Sinclair...Sutures DISCLAIMER The American Academy of Dermatology is not responsible for statements made by faculty. Statements or opinions expressed in this program reflect the views of the faculty and do not reflect the official policy of the American Academy of Dermatology. The information provided at this CME activity is for continuing education purposes 5

6 only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to the diagnostic, management and treatment options of a specific patient s medical condition. 6